| 包装 | 价格(元) |
| 500 µg | 电议 |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 别名 | A-56620-d8 hydrochloride |
| Canonical SMILES | O=C1C2=CC(F)=C(N3C([2H])([2H])C([2H])([2H])NC([2H])([2H])C3([2H])[2H])C=C2N(C4=CC=C(C=C4)F)C=C1C(O)=O.Cl |
| 分子式 | C20H9D8F2N3O3·HCl |
| 分子量 | 429.9 |
| 溶解度 | DMSO: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Sarafloxacin-d8is intended for use as an internal standard for the quantification of sarafloxacin by GC- or LC-MS. Sarafloxacin is a fluoroquinolone antibiotic.1,2It is active against various clinical isolates of bacteria, includingBacteroides, Fusobacterium, Eubacterium, Actinomyces, andPeptococcus(MICs = 0.5-2 µg/ml).1Sarafloxacin inhibitsP. aeruginosaDNA gyrase.3It decreases air sac lesion severity in a chick model ofE. coli-induced colisepticemia when administered at a dose of 8 mg/kg in the drinking water 24 hours per day for five days.2Formulations containing sarafloxacin have previously been used in the treatment of bacterial infections in poultry. 1.Bansal, M.B., and Thadepalli, H.Activity of difloxacin (A-56619) and A-56620 against clinical anaerobic bacteria in vitroAntimicrob. Agents Chemother.31(4)619-621(1987) 2.Charleston, B., Gate, J.J., Aitken, I.A., et al.Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickensAntimicrob. Agents Chemother.42(1)83-87(1998) 3.Moir, D.T., Di, M., Opperman, T., et al.A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agentsJ. Biomol. Screen.12(6)855-864(2007) |
m.cnreagent.com